• Mashup Score: 0
    The Multiple Myeloma Daily - 2 year(s) ago

    A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski

    Source: paper.li
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Myeloma_Doc
      Myeloma_Doc

      The latest The Multiple Myeloma Daily! https://t.co/AygH7rhhjT Thanks to @Haematologica @CancerResearch @NorthTxMSG #melnm #mmsm

  • Mashup Score: 0
    Wolters Kluwer Health - 2 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      A new study found that estrogens promote the establishment of an environment that supports the growth and protection of melanoma tumors: https://t.co/JkbONwxu5t #gynca #melnm #womenshealth #OncNews #camicroenv https://t.co/4fe6l3oK3y

  • Mashup Score: 2
    Wolters Kluwer Health - 2 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      A new study found that estrogens promote the establishment of an environment that supports the growth and protection of melanoma tumors: https://t.co/JkbONwxu5t #gynca #melnm #womenshealth #OncNews #camicroenv https://t.co/Miv3RO8qTD

  • Mashup Score: 0
    Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients - 3 year(s) ago

    Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      Patients w/ stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial & received pembrolizumab post-recurrence derived a 38.8% ORR and a 32% overall 3-year PFS. @ASCO #melnm https://t.co/L2YAlUtfu6 https://t.co/dN7ofLKlB9

Load More